#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Local reactions after snakebite – clinical experience


Authors: Z. Podmanická 1;  S. Dluholucký 1,2;  K. Králinský 1,2;  V. Rajčanová 1
Authors‘ workplace: II. DK SZÚ, Detská fakultná nemocnica s poliklinikou, Banská Bystrica 1;  Fakulta zdravotníctva SZÚ so sídlom v Banskej Bystrici 2
Published in: Čes-slov Pediat 2018; 73 (5): 332-342.
Category: Review

Overview

The authors present a comprehensive view of the current knowledge of Vipera berus in conjunction with the injection of poison (envenomation). Most often it is a seasonal occurrence in the range of spring, summer to autumn months (March – October) and most often it is the Vipera berus. Case reports point to the care and management of patients after snake venom poisoning.

Key words:

Vipera berus, envenomation, snakebite severity score, haemorrhagic swelling, antiserum


Sources

1. Chippaux JP. Epidemiology of snakebites in Europe: a systematic review of the literature. Toxicon 2012 Jan; 59 (1): 86–99.

2. Bátora I. Ako postupovať pri uhryznutí hadom. Int Med 2012; 12 (5): 208–211.

3. Valenta J. Co dělat při ušknutí zmijí obecnou. Int Med 2011; 13 (5): 222–224.

4. Kresánek J. Uhryznutie vretenicou. Lekárnik 2009; 14 (5): 50–51.

5. Dluholucký S, Králinský K, et al. Uhryznutie zmyjou u detí- niektoré kontroverzné otázky a vlastné skúsenosti. Čes-slov Pediat 2001; 56 (9): 438–442.

6. Daley BJ. Snakebite treatmens and management. 2017. [online]. http://emedicine.medscape.com/article/168828-treatment.

7. Swaroop S, Grab B. Snakebite mortality in the world. Bull World Health Organ 1954; 10 (1): 35–76.

8. World Health Organization: Progress in the characterization of venoms and standardization of antivenoms. 58th ed. Geneva: WHO Offset Publication, 1981.

9. Rifaie F, Maharani T, Hamidy A. Where did venomous snakes strike? A Spatial statistical analysis of snakebite cases in Bondowoso regency, Indonesia. HAYATI Journal of Biosciences 2017; 24 (3): 142–148.

10. Bochner R. The international view of envenoming in Brazil: myths and realities. J Venom Anim Toxins Incl Trop Dis 2013; 19( 29): 1–10.

11. Thapar R, Darshan BB, Unnikrishnan B, et al. Clinico-epidemiological profile of snakebite cases admitted in a tertiary care centre in south India: A 5 years study. Toxicol Int 2015; 22 (1): 66–70.

12. Chippaux JP. Snake-bites: appraisal of the global situation. Bull World Health Organ 1998, 76 (5): 515–524. [online] http://www.snakebiteinitiative.org/?page_id=657.

13. Babuj A. Snakebite management. 2015 [online] https://www.slideshare.net/9489649295/snake-bite-management-43980824.

14. Malina T, Babocsay G, Krecsák L, Erdész C. Further clinical evidence for the existence of neurotoxicity in a population of the european adder (Vipera berus berus) in eastern Hungary: second authenticated case. Wilderness Environ Med 2013; 24 (4): 378–383.

15. Malina T, Krecsák L, Jelić D, et al. First clinical experiences about the neurotoxic envenomings inflicted by lowland populations of the Balkan adder, Vipera berus bosniensis. Neurotoxicology 2011; 32 (1): 68–74.

16. De Haro L, Robbe-Vincent A, Saliou B, et al. Unusual neurotoxic envenomations by Vipera aspis aspis snakes in France. Hum Exp Toxicol 2002; 21 (3): 137–145.

17. Ried HA. Adder bites in Britain. Br Med J 1976; 2 (6028): 153–156.

18. Valenta J, Strach Z, Stříteský M, Michálek P. Common viper bites in the Czech Republic – epidemiological and clinical aspects during 15 year period (1999–2013). Prague Med Rep 2014; 115 (3–4): 120–127.

19. Batora I. Uhryznutie vretenicou na Slovensku [online]. Osobitné sdelenie, 4. júla 2018.

20. Chippaux JP. Epidemiology of snakebites in Europe: a systematic review of the literature. Toxicon 2012 Jan; 59 (1): 86–99.

21. Calderón L, Lomonte B, Gutiérrez JM, et al. Biological and biochemical activities of Vipera berus (European viper) venom. Toxicon 1993; 31 (6): 743–753.

22. Czajka U, Wiatrzyk A, Lutyńska A. Mechanism of Vipera berus venom activity and the principles of antivenom administration in treatment. Przegl Epidemiol 2013; 67 (4): 641–646.

23. Gutiérrez JM. Review: Hemorrhage caused by snake venom metalloproteinases: A journey of discovery and understanding. Toxins 2016; 8 (4): 93.

24. Fatima LD, Fatah C. Pathophysiological and pharmacological effects of snake venom components: molecular targets. J Clin Toxicol 2014; 4 (2): 1–9.

25. Valenta J. Terapie ušknutí zmijí obecnou u dětí. Pediatr praxi 2010; 11 (3): 201–203.

26. Santrock D. Crotalide polyvalent antivenin (CroFab) protocol, [online]. http://www.hosp.uky.edu/pharmacy/formulary/criteria/Crotalidae_Polyvalent_Antivenin_Protocol.pdf 2008.

27. Snakebite Treatment First Aid & Emergencies. WebMD. [online]. https://www.webmd.com/first-aid/snakebite-treatment.

28. Reimers AR, Weber M, Müller UR. Are anaphylactic reactions to snake bites immunoglobulin E-mediated? Clin Exp Allergy 2000; 30 (2): 276–282.

29. Gwaltney-Brant SM. Overview of snakebite. MSD manual veterinary manual. [online]. https://www.msdvetmanual.com/toxicology/snakebite/overview-of-snakebite.

30. Gutiérrez JM, Theakston RDG, Warrell DA. Confronting the neglected problem of snake bite envenoming: the need for a global partnership. Eglested Disease, 2006 June.

31. De Silva HA, Ryan NM, De Silva HJ. Adverse reactions to snake antivenom, and their prevention and treatment. Br J Clin Pharmacol 2016; 81 (3): 446–452.

32. Viper venom antitoxin. [online]. file:///C:/Users/zpodmanicka/Downloads/viper-venom-antitoxin-spc%20(2).pdf.

33. Lepak MR, Bochenek SH, Bush SP. Severe adverse drug reaction following crotalidae polyvalent immune Fab (Ovine). Annals of Pharmacotherapy 2015; 49 (1): 145–149.

34. Casewell NR, Al-Abdulla I, Smith D, et al. Immunological cross-reactivity and neutralisation of European viper venoms with the monospecific Vipera berus antivenom ViperaTAb. Toxins (Basel) 2014; 6 (8): 2471–2482.

35. Brvar M, Kurtović T, Grenc D, et al. Vipera ammodytes bites treated with antivenom ViperaTAb: a case series with pharmacokinetic evaluation. Clin Toxicol (Phila) 2017; 55 (4): 241–248.

36. Gold BS, Barish RA, Dart RC, et al. Resolution of compartment syndrome after rattle snake envenomation utilizing non-invasive measures. J Emerg Med 2003; 24 (3): 285–288.

37. Korambayil PM, Ambookan PV, Abraham SV, et al. A multidisciplinary approach with hyperbaric oxygen therapy improve outcome in snake bite injuries. Toxicol Int 2015; 22 (1): 104–109.

38. Hsu CP, Chuang JF, Hsu YP, et al. Predictors of the development of post-snakebite compartment syndrome. Scand J Trauma Resusc Emerg Med 2015; 23 (97): 1–7.

39. Knudsen C, Laustsen AH. Recent advances in next generation snakebite antivenoms. Trop Med Infect Dis 2018; 3 (42): 1–13.

40. Ramos HR, Ho PL. Developing snake antivenom sera by genetic immunization: a review. In: Gopalakrishnakone P, et al. Clinical Toxinology in Asia Pacific and Africa. Dordrecht : Springer Reference, 2015: 401–414.

41. Lewin M, Samuel S, Merkel J, Bickler P. Varespladib (LY315920) appears to be a potent, broad- spectrum, inhibitor of snake venom phospholipase A2 and a possible pre-referral treatment for envenomation. Toxins (Basel) 2016; 8 (9): 1–16.

42 Morjen M, Honoré S, Bazaa A, et al. PIVL, a snake venom Kunitz-type serine protease inhibitor, inhibits in vitro and in vivo angiogenesis. Microvasc Res 2014; 95 (1): 149–156.

43. Gasanov SE, Dagda RK, Rae ED. Snake venom cytotoxins, phospholipase A2s, and Zn2+- dependent metalloproteinases: mechanisms of action and pharmacological relevance. J Clin Toxicol 2014; 4 (1): 1–34.

Labels
Neonatology Paediatrics General practitioner for children and adolescents
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#